Cargando…

New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations

Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the si...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Wei, Li, Fen, Tian, Jing, Xie, Xi, Chen, Jin-Wei, Peng, Xiao-Fei, Tang, Qi, Ge, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013916/
https://www.ncbi.nlm.nih.gov/pubmed/35444448
http://dx.doi.org/10.2147/JIR.S353539
_version_ 1784688101980897280
author Cheng, Wei
Li, Fen
Tian, Jing
Xie, Xi
Chen, Jin-Wei
Peng, Xiao-Fei
Tang, Qi
Ge, Yan
author_facet Cheng, Wei
Li, Fen
Tian, Jing
Xie, Xi
Chen, Jin-Wei
Peng, Xiao-Fei
Tang, Qi
Ge, Yan
author_sort Cheng, Wei
collection PubMed
description Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This may relate to the different inflammatory pathways involved in the osteoarticular and cutaneous symptoms in SAPHO patients. In this study, we provide stratified medication recommendations for SAPHO syndrome. Patients with osteoarticular symptoms can consider tumor necrosis factor blockers, JAK inhibitor, interleukin (IL)-1 inhibitor, and IL-17 inhibitor. Patients with cutaneous symptoms should consider IL-17 and JAK inhibitors. Apremilast, Tripterygium wilfordii Hook F, and bisphosphonates are other effective treatments.
format Online
Article
Text
id pubmed-9013916
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90139162022-04-19 New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations Cheng, Wei Li, Fen Tian, Jing Xie, Xi Chen, Jin-Wei Peng, Xiao-Fei Tang, Qi Ge, Yan J Inflamm Res Review Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome is a rare autoinflammatory disease characterized by dermatological disorders and osteoarticular inflammatory lesions. This article reviews the application of biologics and other treatments based on the therapeutic target and the size of molecules in SAPHO syndrome. We found that drugs, especially biologics, have different effects on bone, joint, and skin damage. This may relate to the different inflammatory pathways involved in the osteoarticular and cutaneous symptoms in SAPHO patients. In this study, we provide stratified medication recommendations for SAPHO syndrome. Patients with osteoarticular symptoms can consider tumor necrosis factor blockers, JAK inhibitor, interleukin (IL)-1 inhibitor, and IL-17 inhibitor. Patients with cutaneous symptoms should consider IL-17 and JAK inhibitors. Apremilast, Tripterygium wilfordii Hook F, and bisphosphonates are other effective treatments. Dove 2022-04-13 /pmc/articles/PMC9013916/ /pubmed/35444448 http://dx.doi.org/10.2147/JIR.S353539 Text en © 2022 Cheng et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Cheng, Wei
Li, Fen
Tian, Jing
Xie, Xi
Chen, Jin-Wei
Peng, Xiao-Fei
Tang, Qi
Ge, Yan
New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
title New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
title_full New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
title_fullStr New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
title_full_unstemmed New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
title_short New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations
title_sort new insights in the treatment of sapho syndrome and medication recommendations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013916/
https://www.ncbi.nlm.nih.gov/pubmed/35444448
http://dx.doi.org/10.2147/JIR.S353539
work_keys_str_mv AT chengwei newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations
AT lifen newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations
AT tianjing newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations
AT xiexi newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations
AT chenjinwei newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations
AT pengxiaofei newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations
AT tangqi newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations
AT geyan newinsightsinthetreatmentofsaphosyndromeandmedicationrecommendations